Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Core Laboratories (CLB) Shares Repurchased (2022 - 2026)

Core Laboratories filings provide 5 years of Shares Repurchased readings, the most recent being $4.0 million for Q1 2026.

  • On a quarterly basis, Shares Repurchased rose 97.68% to $4.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.4 million, a 97.71% increase, with the full-year FY2025 number at $12.4 million, up 134.19% from a year prior.
  • Shares Repurchased hit $4.0 million in Q1 2026 for Core Laboratories, up from $2.7 million in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $5.0 million in Q3 2025 to a low of $1000.0 in Q1 2023.
  • Median Shares Repurchased over the past 5 years was $1.6 million (2022), compared with a mean of $1.7 million.
  • The widest YoY moves for Shares Repurchased: up 4495.45% in 2025, down 45.84% in 2025.
  • Core Laboratories' Shares Repurchased stood at $1.6 million in 2022, then grew by 12.06% to $1.8 million in 2023, then skyrocketed by 174.89% to $4.9 million in 2024, then plummeted by 45.84% to $2.7 million in 2025, then surged by 50.49% to $4.0 million in 2026.
  • The last three reported values for Shares Repurchased were $4.0 million (Q1 2026), $2.7 million (Q4 2025), and $5.0 million (Q3 2025) per Business Quant data.